Group 3 pulmonary hypertension: Challenges and opportunities

Michael McGetterick, Andrew Peacock


[No abstract. Showing first paragraph of article]

Pulmonary hypertension (PH) associated with hypoxia and lung disease, first identified as Group 3 in the 2008 Dana Point classification of PH, is the second most common form of PH and is associated with increased morbidity and mortality. The most common lung diseases resulting in PH are chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and obstructive sleep apnoea (OSA) but is also associated with other diseases, such as cysticfibrosis and high altitude exposure. Those with PH in the setting of obstructive or restrictive lung disease have worse outcomes, but it is not clear if the PH causes increased mortality or whether it is a marker for the severe end of the lung disease spectrum. Patients with Group 3 disease have a worse outcome than Group 1 IPAH. Those patients with Group 1 disease pulmonary arterial hypertension (PAH) but with minor associated lung disease also suffer from worse outcomes.

Full Text:




  • There are currently no refbacks.

Copyright (c) 2020 Michael McGetterick, Andrew Peacock

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.